DLBCL 1L-What to Expect beyond R-CHOP?

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• The R-CHOP protocol has been the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL) for decades, achieving cures in about two-thirds of patients.
• Despite numerous trials, improving outcomes beyond R-CHOP has been challenging due to toxicity and DLBCL's molecular heterogeneity.
• Recent advancements include antibody-drug conjugates and targeted agents, prompting a re-evaluation of first-line treatment strategies.

Purpose of the Study:

• To review findings from phase III trials and phase II studies in first-line (1L) and relapsed/refractory (R/R) DLBCL.
• To discuss the efficacy and potential of novel agents, including chemotherapy-free regimens, in the 1L setting.
• To explore personalized treatment perspectives based on the molecular landscape of DLBCL.

Main Methods:

• Analysis of data from completed phase III first-line (1L) trials in diffuse large B-cell lymphoma (DLBCL).
• Review of piloting phase II studies evaluating novel agents in relapsed/refractory (R/R) and 1L DLBCL settings.
• Survey of chemotherapy-free regimens for efficacy and future potential in 1L DLBCL treatment.

Main Results:

• The POLARIX trial demonstrated superior progression-free survival (PFS) for R-CHP with Polatuzumab Vedotin compared to R-CHOP in first-line DLBCL.
• Targeted agents like Bruton's tyrosine kinase (BTK) inhibitors show activity in specific patient subsets and are under investigation for front-line use.
• Chimeric antigen receptor (CAR) T-cells and T-cell-engaging bispecific antibodies are being explored for earlier lines of therapy.

Conclusions:

• Novel immunochemotherapy regimens, such as R-CHP with Polatuzumab Vedotin, offer improved outcomes in first-line DLBCL.
• Targeted therapies and advanced cell-based treatments like CAR T-cells represent promising avenues for DLBCL treatment, including in earlier lines of therapy.
• Personalized treatment strategies considering DLBCL's molecular heterogeneity are crucial for optimizing outcomes in patients not cured by current standards of care.